Apeloa Pharmaceutical Co Ltd Market Cap ($3.66 Billion)
Market Cap & Net Worth: Apeloa Pharmaceutical Co Ltd (000739)
Apeloa Pharmaceutical Co Ltd market cap. Apeloa Pharmaceutical Co Ltd (SHE:000739) has a market capitalization of $3.66 Billion (CN¥25.00 Billion) as of November 6, 2026. Listed on the SHE stock exchange, this China-based company holds position #4244 globally and #609 in its home market, demonstrating a 10.16% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Apeloa Pharmaceutical Co Ltd's stock price CN¥21.58 by its total outstanding shares 1158443576 (1.16 Billion). Also see cash flow conversion of Apeloa Pharmaceutical Co Ltd for how efficiently the company converts equity into cash flow.
Apeloa Pharmaceutical Co Ltd Market Cap History (2015–2026)
Apeloa Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows growth from $1.25 Billion to $3.66 Billion (11.10% CAGR). Check Apeloa Pharmaceutical Co Ltd (000739) stock price for real-time trading data and today's change.
Apeloa Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Apeloa Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 000739 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.28x
Apeloa Pharmaceutical Co Ltd's market cap is 0.28 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.10x
Apeloa Pharmaceutical Co Ltd's market cap is 3.10 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.16 Billion | $4.77 Billion | $262.90 Million | 0.24x | 4.42x |
| 2017 | $1.01 Billion | $5.55 Billion | $256.59 Million | 0.18x | 3.92x |
| 2018 | $1.17 Billion | $6.38 Billion | $370.56 Million | 0.18x | 3.16x |
| 2019 | $2.06 Billion | $7.21 Billion | $553.40 Million | 0.29x | 3.72x |
| 2020 | $3.73 Billion | $7.88 Billion | $816.73 Million | 0.47x | 4.57x |
| 2021 | $5.67 Billion | $8.94 Billion | $955.55 Million | 0.63x | 5.94x |
| 2022 | $3.52 Billion | $10.54 Billion | $989.17 Million | 0.33x | 3.56x |
| 2023 | $2.56 Billion | $11.47 Billion | $1.06 Billion | 0.22x | 2.42x |
| 2024 | $2.76 Billion | $12.02 Billion | $1.03 Billion | 0.23x | 2.67x |
| 2025 | $2.76 Billion | $9.76 Billion | $890.68 Million | 0.28x | 3.10x |
Competitor Companies of 000739 by Market Capitalization
Companies near Apeloa Pharmaceutical Co Ltd in the global market cap rankings as of November 6, 2026. Also see Apeloa Pharmaceutical Co Ltd assets under control for a full breakdown of the balance sheet.
Key companies related to Apeloa Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Apeloa Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Apeloa Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Apeloa Pharmaceutical Co Ltd's market cap moved from $1.25 Billion to $ 3.66 Billion, with a yearly change of 11.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.66 Billion | +32.64% |
| 2025 | CN¥2.76 Billion | +0.06% |
| 2024 | CN¥2.76 Billion | +7.83% |
| 2023 | CN¥2.56 Billion | -27.43% |
| 2022 | CN¥3.52 Billion | -37.90% |
| 2021 | CN¥5.67 Billion | +51.94% |
| 2020 | CN¥3.73 Billion | +81.16% |
| 2019 | CN¥2.06 Billion | +76.26% |
| 2018 | CN¥1.17 Billion | +16.16% |
| 2017 | CN¥1.01 Billion | -13.39% |
| 2016 | CN¥1.16 Billion | -7.35% |
| 2015 | CN¥1.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Apeloa Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.66 Billion USD |
| MoneyControl | $3.66 Billion USD |
| MarketWatch | $3.66 Billion USD |
| marketcap.company | $3.66 Billion USD |
| Reuters | $3.66 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Apeloa Pharmaceutical Co Ltd
Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People's Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments. It offers API intermediates business, which includes cephalosporin, penicillin, psychotropic, cardiovascular and cerebrovascular, and veterinary API intermediates series; innovative drug R&… Read more